Brown Advisory Inc. Takes Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Brown Advisory Inc. purchased a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 913,087 shares of the medical device company's stock, valued at approximately $32,889,000. Brown Advisory Inc. owned about 1.39% of Tandem Diabetes Care as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Tandem Diabetes Care by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after acquiring an additional 77,451 shares in the last quarter. ArrowMark Colorado Holdings LLC increased its position in Tandem Diabetes Care by 14.1% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock worth $98,108,000 after purchasing an additional 337,026 shares in the last quarter. GW&K Investment Management LLC lifted its stake in Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after purchasing an additional 323,674 shares during the last quarter. Park West Asset Management LLC boosted its position in Tandem Diabetes Care by 49.5% in the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after buying an additional 530,000 shares in the last quarter. Finally, Stephens Investment Management Group LLC grew its stake in shares of Tandem Diabetes Care by 22.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock worth $56,040,000 after buying an additional 281,327 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on TNDM shares. Wells Fargo & Company cut their price objective on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Citigroup cut Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $35.00 to $24.00 in a report on Tuesday, March 4th. Canaccord Genuity Group upped their price objective on Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Finally, Stifel Nicolaus dropped their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $39.81.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.90% of the company's stock.

Tandem Diabetes Care Trading Up 1.1 %

Shares of NASDAQ:TNDM traded up $0.24 during mid-day trading on Friday, hitting $22.98. The company had a trading volume of 1,042,859 shares, compared to its average volume of 1,499,625. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a one year low of $15.75 and a one year high of $53.69. The firm has a fifty day moving average price of $18.59 and a 200 day moving average price of $28.26. The company has a market capitalization of $1.53 billion, a PE ratio of -11.91 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The company had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company's revenue for the quarter was up 22.3% on a year-over-year basis. During the same period last year, the firm posted ($0.65) earnings per share. As a group, research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.